Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026)
Annexon (ANNX) posted quarterly Net Income towards Common Stockholders of -$78.1 million for Q1 2026, down 9.25% year-over-year from -$86.0 million in Q1 2025, and down 61.78% quarter-over-quarter from -$48.3 million in Q4 2025.
Analysis
Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Annexon's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 9.25% year-over-year to -$78.1 million; the TTM figure through Mar 2026 stood at -$232.3 million (down 25.9% YoY), while the FY2025 annual figure was -$208.5 million, down 50.9% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$78.1 million, down from -$48.3 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$29.6 million in Q2 2024, with the low at -$160.9 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$51.0 million (2025), against an average of -$59.2 million.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders sank 367.93% in 2023, then jumped 69.8% in 2024.
- Annexon's Net Income towards Common Stockholders stood at -$34.4 million in 2022, then tumbled by 367.93% to -$160.9 million in 2023, then surged by 69.8% to -$48.6 million in 2024, then increased by 0.69% to -$48.3 million in 2025, then sank by 61.78% to -$78.1 million in 2026.
- Business Quant data shows ANNX's Net Income towards Common Stockholders at -$78.1 million in Q1 2026, -$48.3 million in Q4 2025, and -$54.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Annexon | 978.58 Mn | 978.58 Mn | - | -55.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55.35 Mn |
| Mar 31, 2026 | -46.11 Mn |
| Dec 31, 2025 | -48.26 Mn |
| Sep 30, 2025 | -54.92 Mn |
| Jun 30, 2025 | -51.01 Mn |
| Mar 31, 2025 | -57.51 Mn |
| Dec 31, 2024 | -48.59 Mn |
| Sep 30, 2024 | -34.82 Mn |
| Jun 30, 2024 | -29.61 Mn |
| Mar 31, 2024 | -28.61 Mn |
| Dec 31, 2023 | -29.95 Mn |
| Sep 30, 2023 | -34.73 Mn |
| Jun 30, 2023 | -37.64 Mn |
| Mar 31, 2023 | -41.08 Mn |
| Dec 31, 2022 | -34.38 Mn |
| Sep 30, 2022 | -35.05 Mn |
| Jun 30, 2022 | -37.14 Mn |
| Mar 31, 2022 | -35.37 Mn |
| Dec 31, 2021 | -37.37 Mn |
| Sep 30, 2021 | -35.60 Mn |